Clinical trials
First-Line clinical trials
Below are recruiting first-line clinical trials, each written for real people, not researchers. We’re tracking 399 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07216703RecruitingPhase 3
Study of sacituzumab tirumotecan plus pembrolizumab for cervical cancer
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
Birmingham, AlabamaAges 18 years+ - NCT07209059RecruitingPhase 2
Nivolumab plus first-line therapy for advanced Hodgkin lymphoma
This trial tests whether adding the immunotherapy drug nivolumab to the first treatment of advanced Hodgkin lymphoma can improve outcomes. It uses PET scans to guide therapy, potentially reducing the need for stronger chemotherapy.
MoscowAges 18–60 - NCT07185997RecruitingPhase 3
Study of Firmonertinib for first-line treatment of advanced lung cancer with uncommon EGFR mutations
This trial tests a new pill called firmonertinib against standard EGFR inhibitor pills for people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations. It aims to see if firmonertinib works better in stopping the cancer from growing.
Fullerton, CaliforniaAges 18 years+ - NCT06945705RecruitingPhase 2
Targeted therapy for EGFR-mutant lung cancer with brain spread
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
ZhengzhouAges 18 years+ - NCT07190677Recruiting
Nivolumab plus ipilimumab with chemo for advanced lung cancer
This trial tests combining two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy as a first treatment for advanced lung cancer that has spread or come back. It may help if your cancer hasn't been treated before and doesn't have certain genetic changes.
Pavia, LombardyAges Any age - NCT07188896RecruitingPhase 2
Immunotherapy combinations for advanced kidney cancer
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07185633RecruitingPhase 2
Study of Gecacitinib and Steroids for Acute Graft-Versus-Host Disease
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
Suzhou, JiangsuAges 18 years+ - NCT07179484Recruiting
Study of CT041 for advanced stomach or junction cancer after first treatment
This trial tests a new cell therapy (CT041) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CLDN18.2. It is given after initial chemotherapy to try to keep the cancer from growing.
BeijingAges 18–75 - NCT07178795RecruitingPhase 3
New drug vs standard care for HER2-mutant lung cancer
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT07176650RecruitingPhase 1
Testing a biosimilar ipilimumab for advanced liver cancer
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Glendale, CaliforniaAges 18–65 - NCT07165951RecruitingPhase 3
Study of new drug combo for first treatment of advanced pancreatic cancer
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
Hefei, AnhuiAges 18–75 - NCT07169552RecruitingPhase 2
HC010 for first-line PD-L1 positive advanced lung cancer
This trial tests a new drug called HC010 as a first treatment for people with advanced non-small cell lung cancer that is PD-L1 positive. It aims to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07171606RecruitingPhase 2
Study of a new drug for advanced lung cancer
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
ShanghaiAges 18–75 - NCT07163273RecruitingPhase 2
Alternating chemotherapy for first-line metastatic pancreatic cancer
This study tests a monthly rotation of two chemotherapy combinations (NALIRIFOX and GnP) as the first treatment for metastatic pancreatic cancer. The goal is to see if alternating the drugs helps control the cancer while reducing side effects.
Bay Shore, New YorkAges 18 years+ - NCT07155174RecruitingPhase 2
Testing new drug combo for first-line extensive small cell lung cancer
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
New Haven, ConnecticutAges 18 years+ - NCT07147101Recruiting
Immunotherapy for advanced liver cancer: a study on effectiveness and immune response
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07143045Recruiting
Zorifertinib for lung cancer that has spread to the brain
This trial tracks how well zorifertinib works as a first treatment for people with a specific type of advanced lung cancer that has spread to the brain or spinal cord lining. Participants may receive zorifertinib or another standard treatment, and researchers will monitor their response over time.
Hefei, AnhuiAges 18 years+ - NCT06962267RecruitingPhase 2
Study of TQB2916 with chemo for advanced pancreatic cancer
This trial tests a new drug (TQB2916) combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for metastatic pancreatic cancer. It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07122024RecruitingPhase 4
Testing a dual therapy for H. pylori treatment
This trial tests a two-drug treatment (keverprazan and amoxicillin) for people who have H. pylori and have not been treated for it before. The goal is to see if this newer combination works well and is safe.
Hangzhou, ZhejiangAges 18–65 - NCT07109154Recruiting
Study of lung cancer treatment patterns in the real world
This study looks at the medical records of people with advanced non-small cell lung cancer to understand what treatments they received and whether those treatments follow official guidelines. It may help doctors learn how to improve care for future patients.
RecifeAges Any age - NCT07110038RecruitingPhase 2
Study of Enfortumab Vedotin Plus Avelumab for Advanced Penile Cancer
This trial tests a combination of two drugs (enfortumab vedotin and avelumab) as a first treatment for men with advanced or metastatic penile cancer that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors and improve outcomes.
DresdenAges 18 years+ - NCT07110064RecruitingPhase 2
A new combo therapy for advanced pancreatic cancer
This trial tests a combination of three drugs (QL1706, lenvatinib, and chemotherapy) as the first treatment for people with advanced pancreatic cancer that has spread to other parts of the body. It aims to see if this combination is safe and effective.
NanjingAges 18 years+ - NCT07096362RecruitingPhase 2
Using a blood test to guide treatment for advanced pancreatic cancer
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
Miami, FloridaAges 18 years+ - NCT07101679RecruitingPhase 2
Study of radiation, chemo, and immunotherapy for advanced pancreatic cancer
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–75
Hear when a new First-Line trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first-line?
- Yes. Clin2 currently lists 399 recruiting first-line studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first-line trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first-line trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.